NCT02652377View on ClinicalTrials.gov

EDP-494-001: A Study of EDP-494 in Healthy Subjects and Hepatitis C Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

January 10, 2016

Primary Completion Date

December 27, 2016

Study Completion Date

December 27, 2016

Conditions
Hepatitis C
Interventions
DRUG

EDP-494

10, 100 and 200 mg capsules

DRUG

Placebo

placebo to match EDP-494

Trial Locations (1)

1150

Auckland Clinical Studies Ltd, Auckland

Sponsors
All Listed Sponsors
collaborator

Novotech (Australia) Pty Limited

INDUSTRY

lead

Enanta Pharmaceuticals, Inc

INDUSTRY